SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Pedersen Terje)) pers:(Hartmann Anders)
 

Search: (WFRF:(Pedersen Terje)) pers:(Hartmann Anders) > Effect of fluvastat...

  • Fellström, BengtUppsala universitet,Institutionen för medicinska vetenskaper (author)

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial

  • Article/chapterEnglish2004

Publisher, publication year, extent ...

  • Elsevier BV,2004
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-105019
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-105019URI
  • https://doi.org/10.1111/j.1523-1755.2004.00919.xDOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-48286URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Hyperlipidemia is a risk factor for long-term renal transplant dysfunction, but no prospective clinical trials have investigated the effects of statin treatment on graft function in renal transplant recipients. The aim of the present study was to evaluate the effect of fluvastatin on long-term renal transplant function and development of chronic allograft nephropathy in the ALERT (Assessment of Lescol in Renal Transplantation) study. METHODS: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin, 40 mg and 80 mg daily, in renal transplant recipients. Patients were randomized to receive either fluvastatin (N= 1050) or placebo (N= 1052) and followed for five to six years. Renal end points included graft loss or doubling of serum creatinine or death; glomerular filtration rate (GFR) was also measured during follow-up in a subset of patients (N= 439). RESULTS: There were 283 patients (13.5%) with graft loss, mainly due to chronic rejection (82%), yielding an annual rate of 2.4%. Fluvastatin treatment significantly lowered mean low-density lipoprotein (LDL)-cholesterol levels by 32% (95% CI -33 to -30) compared with placebo, but had no significant effect on the incidence of renal graft loss or doubling of serum creatinine, or decline in GFR throughout follow-up in the whole study population. Neither was any treatment effect by fluvastatin found in any of the subgroups analyzed. CONCLUSION: Fluvastatin treatment significantly improves lipid values in renal transplant recipients but has no effect on graft loss or doubling of serum creatinine.

Subject headings and genre

  • lipoprotein
  • renal
  • transplantation
  • HMG-CoA reductase inhibitor
  • chronic rejection
  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Holdaas, Hallvard (author)
  • Jardine, Alan G. (author)
  • Holme, Ingar (author)
  • Nyberg, Gudrun (author)
  • Fauchald, Per (author)
  • Grönhagen-Siska, Carola (author)
  • Madsen, Sören (author)
  • Neumayer, Hans-Hellmut (author)
  • Cole, Edward (author)
  • Maes, Bart (author)
  • Ambühl, Patrice (author)
  • Olsson, AndersÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Internmedicin,Endokrin- och magtarmmedicinska kliniken US(Swepub:liu)andol21 (author)
  • Hartmann, Anders (author)
  • Logan, John O. (author)
  • Pedersen, Terje R. (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Kidney International: Elsevier BV66:4, s. 1549-15550085-25381523-1755

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view